Rebamipide has low oral bioavailability (10%) due to its low solubility and permeability. Lipid nanoemulsions (LNEs) were prepared in order to improve its oral bioavailability. Rebamipide-loaded lipid nanoemulsions were formulated by hot homogenization and ultrasonication method. Olive oil and egg lecithin in various concentrations as emulsifier were used in the preparation of LNEs. The lipid nanoemulsions were evaluated for various parameters. The globule size, polydispersity index (PDI), and zeta potential (ZP) of the formulations ranged from 230.3 ± 3.88 to 279.8 ± 5.76 nm, 0.204 ± 0.008 to 0.246 ± 0.029, and − 27.7 ± 2.05 to − 31.0 ± 1.87 mV, respectively. Entrapment efficiency and assay values ranged from 99.90 ± 0.006 to 99.92 ± 0.002% and 99.3 ± 0.808 to 99.6 ± 0.360, respectively. Physical stability test results revealed that the optimized LNEs were stable for 2 months at both room (25°C) and refrigerated temperature (4°C). The optimized LNE showed 4.32-fold improvement in the oral bioavailability in comparison to a marketed tablet suspension. In vivo anti ulcer activity of rebamipide LNE was studied by testing the prophylactic effect in preventing the mucosal damage in stomach region. The mucosa of stomach in animals was damaged by per oral administration of 80% alcohol. Maximum prophylactic antiulcer activity was observed by per oral delivery of rebamipide as LNE. Our results indicated that LNEs were a promising approach for the oral delivery of rebamipide for systemic effects along with local effects in protecting gastric region, which gets damaged during peptic ulcers.
This is a preview of subscription content, log in to check access.
The authors thank UCPSc, KU, Warangal for providing all the requirements to carry out research. Further, the authors thank Prof. Veerabhadra Rao, pathologist of M/s. VBR Diagnostics, for help in histopathological studies.
Compliance with Ethical Standards
Ethical Committee Approval
The animal protocol was approved by the IAEC (Protocol no. IAEC/4/UCPSC/KU/2017). The animal treatment in the study was according to CPCSEA guidelines.
The authors declare that there is no conflict of interest.
Tung NT, Park CW, Oh TO, Kim JY, Ha JM, Rhee YS, et al. Formulation of solid dispersion of rebamipide evaluated in a rat model for improved bioavailability and efficacy. J Pharm Pharmacol. 2011;63(12):1539–47.CrossRefGoogle Scholar
Genta RM. The role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003;18(Suppl. 1):8–13.CrossRefGoogle Scholar
Kim KT, Lee J-Y, Park J-H, Cho H-J, Yoon I-S, Kim D-D. Capmul MCM/Solutol HS15-based microemulsion for enhanced oral bioavailability of rebamipide. J Nanosci Nanotechnol. 2017;17:2340–4.CrossRefGoogle Scholar
Pradhan R, Tran TH, Choi JY, Choi IS, Choi HG, Yong CS, et al. Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability. Arch Pharm Res. 2015;38:522–33.CrossRefGoogle Scholar
Guo Y, Wang Y, Xu L. Enhanced bioavailability of rebamipide nanocrystal tablets: formulation and in vitro/in vivo evaluation. Asian J Pharm Sci. 2015;10(3):223–9.CrossRefGoogle Scholar
Deitel M, Friedman KL, Cunnane S, Lea PJ, Chaiet A, Chong J, et al. Emulsion stability in a total nutrient admixture for total parenteral nutrition. J Am Coll Nutr. 1992;11:5–10.CrossRefGoogle Scholar
Gettings SD, Lordo RA, Feder PI, Hintze KL. A comparison of low volume, draize and in vitro eye irritation test data. II. Oil/water emulsions. Food Chem Toxicol. 1998;36:47–59.CrossRefGoogle Scholar
Mizushima Y. Lipid microspheres (lipid emulsions) as a drug carrier—an overview. Adv Drug Deliv Rev. 1996;20:113–5.CrossRefGoogle Scholar
Singh M, Ravin LJ. Parenteral emulsions as drug carrier systems. J Parenter Sci Technol. 1986;40:34–41.PubMedGoogle Scholar
Takino T, Konishi K, Takakura Y, Hashida M. Long circulating emulsion carrier systems for highly lipophilic drugs. Biol Pharm Bull. 1994;17:121–5.CrossRefGoogle Scholar
Floyd AG. Top ten considerations in the development of parenteral emulsions. Pharm Sci Technol Today. 1999;2:134–43.CrossRefGoogle Scholar
Devalapally H, Silchenko S, Zhou F, McDade J, Goloverda G, Owen A, et al. Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs. J Pharm Sci. 2013;102(10):3808–15.CrossRefGoogle Scholar
Patel Y, Poddar A, Sawant K. Formulation and characterization of cefuroxime Axetil nanoemulsion for improved bioavailability. J Pharm Bioallied Sci. 2012;4(Suppl 1):S4–5.PubMedPubMedCentralGoogle Scholar
Zhao L, Wei Y, Huang Y, He B, Zhou Y, Fu J. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:3769–79.CrossRefGoogle Scholar
Sun L, Wan K, Hu X, Zhang Y, Yan Z, Feng J, et al. Functional nanoemulsion-hybrid lipid nanocarriers enhance the bioavailability and anti-cancer activity of lipophilic diferuloylmethane. Nanotechnology. 2016;27(8):085102.CrossRefGoogle Scholar
Varshika E, Prabhakar K, Kishan V. Preparation, characterization and in vivo pharmacodynamic evaluation of parenteral diclofenac submicron lipid emulsions. PDA J Pharm Sci Technol. 2009;63(2):380–9.PubMedGoogle Scholar
Afzal SM, Shareef MZ, Dinesh T, Kishan V. Folate-PEG-decorated docetaxel lipid nanoemulsion for improved antitumor activity. Nanomedicine (London). 2016;11(16):1–10.CrossRefGoogle Scholar
Muzammil Afzal S, Naidu VG, Harishankar N, Kishan V. Albumin anchored docetaxel lipid nanoemulsion for improved targeting efficiency—preparation, characterization, cytotoxic, antitumor and in vivo imaging studies. Drug Deliv. 2016;23(4):1355–63.PubMedGoogle Scholar
Syed MA, Veerabrahma K. Biodegradable preparation, characterization and in vitro evaluation of stealth docetaxel lipid nanoemulsions for efficient cytotoxicity. Int J Drug Deliv. 2013;5:188–95.Google Scholar
Geng T-Y, Xu C, Xu G-H. Albumin conjugated lipid nanoemulsion for site specific delivery of rapamycin at inflammatory site of spinal cord injury. Int J Clin Exp Med. 2016;9(11):21028–37.Google Scholar
Kandadi P, Syed MA, Goparaboina S, Veerabrahma K. Albumin coupled lipid nanoemulsions of diclofenac for targeted delivery to inflammation. Nanomed. 2012;8:1162–71.CrossRefGoogle Scholar
Kandadi P, Syed MA, Goparaboina S, Veerabrahma K. Brain specific delivery of pegylated indinavir submicron lipid emulsions. Eur J Pharm Sci. 2011;42:423–32.CrossRefGoogle Scholar
Prabhakar K, Afzal SM, Surender G, Kishan V. Tween 80 containing lipid nanoemulsions for delivery of indinavir to brain. Acta Pharm Sin B. 2013;3(5):345–53.CrossRefGoogle Scholar
Krishna G, Wood GC, Sheth BB. Improving emulsification efficacy of lecithin by formulation design. I: effect of adding a secondary surfactant. PDA J Pharm Sci Technol. 1998;52(6):331–6.PubMedGoogle Scholar
Liu Y, Yu X-M, Sun R-J, Pan X-L. Folate-functionalized lipid Nanoemulsion to deliver chemo-radiotherapeutics together for the effective treatment of nasopharyngeal carcinoma. AAPS PharmSciTech. 2017;18(4):1374–81.CrossRefGoogle Scholar
Madishetty S, Afzal SM, Prabhakar K, Kishan V. Cationic diclofenac lipid Nanoemulsion for improved oral bioavailability: preparation, characterization and in vivo evaluation. Int J Pharm Sci Nanotech. 2015;8(2):2874–80.Google Scholar
Li C-Y, Xu H-D, Zhao B-T, Chang H-I, Rhee H-I. Gastroprotective effect of cyanidin 3-glucoside on ethanol-induced gastric lesions in rats. Alcohol. 2008;42:683–7.CrossRefGoogle Scholar
Shotton E, Davis SS. A note on the stability of emulsion on high dilution. J Pharm Pharmacol. 1968;20:825–9.CrossRefGoogle Scholar
Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev. 1997;25:71–89.CrossRefGoogle Scholar
Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28–49.CrossRefGoogle Scholar